TABLE 2

Clinical characteristics in the tigecycline and comparison groups

CharacteristicTigecycline group (n = 17)Comparison group (n = 65)P value
Demographic characteristic
    Age (median [IQR]) (yr)80 (62.5–83)76 (68.5–82)0.693
    Male (no. [%])12 (70.6)50 (76.9)0.752
APACHE II score within 24 h of bacteremia onset (median [IQR])27 (22.5–32.5)24 (21.5–30)0.375
APACHE II score > 25 (no. [%])11 (64.7)29 (44.6)0.177
Comorbid condition (no. [%])
    Type 2 diabetes mellitus5 (29.4)18 (27.7)>0.999
    Chronic obstructive pulmonary disease5 (29.4)8 (12.3)0.130
    Coronary artery disease4 (23.5)6 (9.2)0.204
    Congestive heart failure5 (29.4)4 (6.2)0.016
    Renal impairment5 (29.4)11 (16.9)0.304
    End-stage renal disease4 (23.5)1 (1.5)0.006
    Cerebrovascular accident3 (17.6)14 (21.5)>0.999
    Collagen vascular disease0 (0.0)1 (1.5)>0.999
    Malignancy7 (41.2)25 (38.5)>0.999
Median hospital duration prior to bacteremia, days (IQR)22 (15–59.5)14 (6–36)0.081
Mechanical ventilator use at bacteremia onset (no. [%])13 (76.5)32 (49.2)0.057
Acquired in intensive care unit (no. [%])13 (76.5)53 (81.5)0.732
Infection source (no. [%])
    Respiratory tract14 (82.4)39 (60.0)0.098
    Urinary tract1 (5.9)6 (9.2)>0.999
    Intra-abdominal1 (5.9)4 (6.2)>0.999
    Skin and soft tissue0 (0.0)1 (1.5)>0.999
    Catheter related1 (5.9)2 (3.1)>0.999
    Central nervous system0 (0.0)2 (3.1)>0.999
    Primary bacteremia0 (0.0)11 (16.9)0.109
Isolates with Acinetobacter baumannii (no. [%])11 (64.7)65 (100.0)<0.001
Susceptible antimicrobial agent at the day of bacteremia onset (no. [%])12 (70.6)26 (40.0)0.031
Dual appropriate antimicrobial agents (no. [%])a4 (23.5)4 (6.2)0.054
14-day mortality rate (no. [%])7 (41.2)9 (13.8)0.018
  • a Dual appropriate antimicrobial agents was defined as ≥2 intravenous antibiotics, to which the bacterium was susceptible, at an appropriate dose within 2 days of bacteremia onset.